
|Articles|January 1, 2008
Monitor PSA closely in testosterone therapy patients
Although there is no confirmed direct link between testosterone replacement therapy and prostate cancer, a recent study suggests that physicians treating middle-aged hypogonadal men with extrinsic testosterone should be more vigilant in monitoring these patients' PSA levels than they would be in monitoring average men of the same age.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
FDA approves generic Ga-68 PSMA-11 radiodiagnostic for prostate cancer
3
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
4
Benjamin Lowentritt, MD, reviews real-world testosterone recovery data with relugolix
5











